Regardless of the published sequences of the aptamers against the S1 protein of SARS-CoV-2, only two aptamers, namely ApTOLL targeting toll-like receptor 4 for COVID-19 therapeutics and AptamerX used for saliva-based COVID-19 diagnosis targeting the S protein, have previously been in clinical trials.12 This evidence concerns the gene TLR4 and COVID-19.